Adjunct Professor of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine

Associate Director, Center for Targeted Therapeutics and Translational Nanomedicine

Consultant to investment firms and life science funding organizations, including the Gates Foundation. Preclinical strategy consultant to early-stage biotechnology companies. Focus on oligonucleotide therapeutics, biologics, and targeted delivery technologies.

Member of the RNA Therapeutics Executive Team; innovation and implementation of external collaboration strategy.Scientific Liaison for external collaborations and co-Chair of the RNA Research and Licensing Committee.Responsible for targeted siRNA delivery strategy and implementation of pharmacology models, and for external collaborations on targeted delivery technologies.

Member Biologics Discovery Review Committee. Led post-S-P merger effort to integrate project governance. Directed discovery efforts for several novel and biosimilar monoclonal antibody programs, including Fc effector risk assessment and IND enabling studies for Merck BioVenture programs.

Preclinical R&D; increasing levels of responsibility for discovery and development efforts for novel oncology programs, including farnesyl transferase (L-778123), KSP (MK-0731), IGF-1R antibody (MK-0646), and AKT (MK-2206).